Jeffrey G. Black

Jeffrey G. Black (finance chief) discloses dealings in 3 companies, chiefly Apollo Endosurgery, Inc., Exagen Inc. and Standard Biotools Inc. In total, 17 filings cover trades dated from 11 August 2021 to 12 March 2026.

Both buying and selling appear: 4 purchases worth €412k, against 2 sales worth €177k. On balance, insiders were net buyers of €235k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 8 share grants and 2 option exercises. 2026 to date brings no purchases and 1 sale.

Half of the purchases are above €81k and half below. 2 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 16 March 2026: a share grant of €205k, in Exagen Inc. The clock since the last published purchase (19 November 2024) now reads 698 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.